Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat
暂无分享,去创建一个
John P. Kelly | J. Kelly | G. Boland | Eamond D. O'Loinsigh | Gerard Boland | Kathy M. O'Boyle | K. O’boyle | E. O'Loinsigh
[1] P. Dyment,et al. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. , 1994, Journal of American college health : J of ACH.
[2] M. P. Johnson,et al. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.
[3] J. O'Callaghan,et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat , 1991, Pharmacology Biochemistry and Behavior.
[4] M. Colado,et al. In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism , 1999, Neuropharmacology.
[5] E. D. De Souza,et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.
[6] M. Geyer,et al. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. , 1988, The Journal of pharmacology and experimental therapeutics.
[7] Y. Claustre,et al. Characterization of [3H]paroxetine binding to rat cortical membranes. , 1985, European journal of pharmacology.
[8] J. Langston,et al. 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. , 1987, European journal of pharmacology.
[9] M. Colado,et al. In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine , 1997, British journal of pharmacology.
[10] G. Ricaurte,et al. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.
[11] G. Hanson,et al. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. , 1987, European journal of pharmacology.
[12] J. Kelly,et al. Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats , 1995, Pharmacology Biochemistry and Behavior.
[13] M. P. Johnson,et al. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. , 1991, European journal of pharmacology.
[14] A. R. Green,et al. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.
[15] M. Geyer,et al. The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[16] G. Battaglia,et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] M. Colado,et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.
[18] M. Pranzatelli,et al. The relation of central 5-HT1A and 5-HT2 receptors: Low dose agonist-induced selective tolerance in the rat , 1991, Pharmacology Biochemistry and Behavior.
[19] L. Seiden,et al. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.
[20] D E Nichols,et al. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.
[21] D. E. N. A. R. Oberlender. STRUCTURE-ACTIVITY RELATIONSHIPS OF MPMA AND RELATED COMPOUNDS : A NEW CLASS OF PSYCHOACTIVE AGENTS ? , 2022 .
[22] A. Shulgin,et al. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). , 1980, Journal of pharmaceutical sciences.
[23] D. E. Nichols,et al. Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? a , 1990, Annals of the New York Academy of Sciences.
[24] J. Nash. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. , 1990, Life sciences.
[25] M. Spitzer,et al. Psychological Effects of MDE in Normal Subjects , 1993, Neuropsychopharmacology.
[26] C. J. Schmidt,et al. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. , 1991, The Journal of pharmacology and experimental therapeutics.
[27] C. J. Schmidt,et al. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors , 1990, Brain Research.
[28] D. Mckenna,et al. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine , 1991, Pharmacology Biochemistry and Behavior.
[29] J. Nash,et al. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. , 1991, European journal of pharmacology.
[30] M. Wheaton,et al. THE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, “ECSTASY”) ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL NERVOUS SYSTEM , 1996, Progress in Neurobiology.
[31] W. Lovenberg,et al. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.
[32] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[33] L. Seiden,et al. Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.
[34] M. Molliver. Serotonergic Neuronal Systems: What Their Anatomic Organization Tells Us about Function , 1987, Journal of clinical psychopharmacology.
[35] C. J. Schmidt. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. , 1987, European journal of pharmacology.
[36] C. J. Schmidt,et al. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.
[37] M. Colado,et al. Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.
[38] T. Greve,et al. An automated direct-injection HPLC-method for the electrochemical/fluorimetric quantitation of monoamines and related compounds optimized for the screening of large numbers of animals. , 1986, Biomedical chromatography : BMC.
[39] L. Seiden,et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.
[40] B. Yamamoto,et al. Mazindol Attenuates the 3,4‐Methylenedioxymethamphetamine‐Induced Formation of Hydroxyl Radicals and Long‐Term Depletion of Serotonin in the Striatum , 1999, Journal of neurochemistry.
[41] L S Seiden,et al. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.
[42] J. Tracey,et al. Ecstasy abuse in Ireland. , 1993, Irish medical journal.
[43] M. Colado,et al. The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). , 1999, Pharmacology & toxicology.
[44] C. J. Schmidt,et al. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. , 1991, European journal of pharmacology.
[45] S. Peroutka. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA , 1990, Topics in the Neurosciences.